It is always a pleasure and a privilege to bring to all of you updates on InPOG. These newsletters, which are disseminated far and wide, provide a snapshot of the much needed progress being made. This newsletter at the end of the term of the present InPOG Executive is particularly special to us as it gives an opportunity to reflect and assess what we are doing.

Martin Luther King once famously said “I have a dream”. One such dream we all share is to improve outcomes of children with cancer in India. InPOG was created to use the tool of co-operative research and multicenter trials to help us get closer to our dream. Three years ago the first InPOG Executive was entrusted with the responsibility of taking this forward. The salient activities of the Executive have been as follows:

- Built InPOG membership
- Developed subcommittees and defined role of subcommittee chairs
- Laid out broad policies and developed a study roadmap
- Provided updates at PHOCON/Mid-term CME including presenting results of InPOG studies
- Disseminated information through newsletters, PHOJ and the PHO IAP website

The subcommittee chairs and members, along with our colleagues have led the way in initiating and conducting studies. As of December 2017, there are 23 studies registered with eight recruiting and one which has finished recruitment. All this is very exciting and inspiring for all of us. We do not for a moment forget that there is really a very long way to go. And in that journey we wish the new InPOG Executive led by Dr Sripad Banavali, all the best. We thank everyone for their support and encouragement. We bid adieu with a quote by a man who inspired Martin Luther King and who we all affectionately call Bapu

“Be the change that you wish to see in the world”
A Summary of the Progress

2014 December
0 recruiting studies, 0 recruiting centres, 0 recruited patients

2015 December
1 recruiting study, 11 recruiting centres, 38 recruited patients

2016 December
5 recruiting studies, 32 recruiting centres, 369 recruited patients

2017 December
9 recruiting studies, 41 recruiting centres, 1783 recruited patients
<table>
<thead>
<tr>
<th>Subcommittee</th>
<th>Provisional Registration</th>
<th>Full Registration</th>
<th>Recruitment Ongoing</th>
<th>Recruitment Complete</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td></td>
<td></td>
<td>InPOG-ALL-15-01</td>
<td></td>
</tr>
<tr>
<td>AML</td>
<td></td>
<td></td>
<td>InPOG-AML-16-01</td>
<td></td>
</tr>
<tr>
<td>Ch Myelop Dis</td>
<td>InPOG-CML-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HL</td>
<td>InPOG-HL-17-02</td>
<td>InPOG-HL-15-01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHL</td>
<td></td>
<td></td>
<td>InPOG-NHL-16-01</td>
<td></td>
</tr>
<tr>
<td>Histiocytosis</td>
<td></td>
<td></td>
<td>InPOG-HIST-17-01</td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>InPOG-RB-17-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>InPOG-WT-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>InPOG-LIV-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNET</td>
<td>InPOG-PNET-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft Tissue Sarcoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germ Cell Tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rare, epithelial</td>
<td>InPOG-RARE-17-02</td>
<td>InPOG-RARE-17-01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSCT</td>
<td>InPOG-HSCT-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Access to Care</td>
<td>InPOG-ACC-16-02</td>
<td>InPOG-ACC-16-03</td>
<td>InPOG-ACC-16-01</td>
<td></td>
</tr>
<tr>
<td>Supportive Care</td>
<td>InPOG-SUPP-16-02</td>
<td>InPOG-SUPP-16-01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidemiology</td>
<td>InPOG-EPI-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late Effects</td>
<td>InPOG-LE-17-02</td>
<td>InPOG-LE-16-01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palliative Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Genetics</td>
<td>InPOG-CANGEN-16-01</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
InPOG studies granted full registration

InPOG-HL-15-01

A collaborative study for newly diagnosed childhood Hodgkin’s lymphoma patients in India

Principal Investigator
Prof Jagdish Chandra

Registered with InPOG
June 2015

CTRI Registration
CTRI/2016/03/010916

Recruitment commenced
August 2015

Currently patients recruited
362

Target patient recruitment
350 revised to 400

Anticipated duration of recruitment
3 years

Centers study open in
27 centres

- All India Institute of Medical Sciences, New Delhi
- All India Institute of Medical Sciences, Patna
- Amrita Institute of Medical Sciences, Kochi
- Asian Institute of Oncology, Mumbai
- Banaras Hindu University, Varanasi
- Cancer Institute, Chennai
- Christian Medical College, Ludhiana
- Deenanath Mangeshkar Hospital, Pune
- Fortis Memorial Research Institute, Gurgaon
- Government Medical College, Jammu
- GVN Cancer Institute, Trichy
- Hematology-Oncology Clinic, Ahmedabad
- Indraprastha Apollo Hospital, New Delhi
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- JIPMER, Puducherry
- Kalawati Children’s Hospital, New Delhi
- King George’s medical University, Lucknow
- Mahaveer Cancer Sansthan, Patna
- Max Super Specialty Hospital, Saket, New Delhi
- Mazumdar Shaw Cancer Centre, Bangalore
- Meenakshi Mission Hospital & Research Centre, Madurai
- MNJ Cancer Hospital, Hyderabad
- Rainbow Children’s Hospital, Hyderabad
- Rajiv Gandhi Cancer Institute, New Delhi
- Regional Cancer Centre, Thiruvananthapuram
- Saroj Gupta Cancer Centre and research Institute, Kolkata
- Sir Ganga Ram Hospital, New Delhi
InPOG-ALL-15-01

An Indian Childhood Collaborative Leukemia Group multicentre national standardization study for newly diagnosed acute lymphoblastic leukemia

 Principal Investigator Prof Vaskar Saha
 Registered with InPOG July 2015
 CTRI Registration CTRI/2015/12/006434
 Recruitment commenced Oct 2016
 Currently patients recruited 128
 Target patient recruitment 2240
 Centers study open in 4 centres

▪ All India Institute of Medical Sciences, New Delhi
▪ Cancer Institute, Chennai – NEW
▪ PGIMER, Chandigarh – NEW
▪ Tata Medical Centre, Kolkata

InPOG-AML-16-01

Randomized Phase III Study Comparing DA (3+7) Versus ADE as Induction Chemotherapy in children with Acute Myeloid Leukemia

 Principal Investigator Dr Venkatraman Radhakrishnan
 Registered with InPOG April 2016
 CTRI Registration CTRI/2014/11/005202
 Recruitment commenced July 2014
 Currently patients recruited 81
 Target patient recruitment 700
 Anticipated duration of recruitment 5 years
 Centers study open in 4 centres

▪ Cancer Institute, Chennai
▪ Institute Rotary Cancer Hospital, AIIMS, New Delhi
▪ JIPMER, Puducherry - NEW
▪ MNJ Cancer Hospital, Hyderabad
InPOG-LE-16-01

The Indian Childhood Cancer Survivorship Study (C2S study): After treatment completion registry of childhood cancers – Phase 1

Principal Investigator  Dr Rachna Seth
Registered with InPOG  May 2016
CTRI Registration
Recruitment commenced  June 2016
Currently patients recruited  539
Target patient recruitment  At least 500 (desirable 1000)
Anticipated duration of recruitment  5 years
Centers study open in  11 centres

- All India Institute of Medical Sciences, New Delhi
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Kalawati Children’s Hospital, New Delhi
- King George’s medical University, Lucknow
- Max Super Specialty Hospital, Patparganj, New Delhi - NEW
- Max Super Specialty Hospital, Saket, New Delhi
- Rajiv Gandhi Cancer Institute, New Delhi
- Regional Cancer Centre, Thiruvananthipuram - NEW
- SION Hospital, Mumbai
- Tata Medical Centre, Kolkata

InPOG-PNET-16-01

Evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes in patients with PNET of Kidney: An InPOG study

Principal Investigator  Dr Bivas Biswas
Registered with InPOG  June 2016
CTRI Registration
Recruitment commenced  Yes
Currently patients recruited  25
Target patient recruitment  At least 50
Anticipated duration of recruitment  6 months
Centers study open in  2 centres

- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- Tata Medical Centre, Kolkata
InPOG-SUPP-16-01

A Prospective Open-labeled Randomized Control Trial of Proactive Enteral Nutrition Versus Standard of Care in Children with Cancer and High Nutritional Risk

Principal Investigator          Dr Brijesh Arora
Registered with InPOG          July 2016
CTRI Registration
Recruitment commenced          No
Currently patients recruited   NA
Target patient recruitment     230
Anticipated duration of recruitment 2 years
Centers study open in          NA

InPOG NHL-16-01

A Retrospective Multi-centric Study of Contemporary Epidemiology & Outcome of Childhood B-NHL in India

Principal Investigator          Dr Amita Trehan
Registered with InPOG           October 2016
CTRI Registration
Recruitment commenced          Yes
Currently patients recruited   238
Target patient recruitment     300-400
Anticipated duration of recruitment 6 months
Centers study open in          11 centres

- All India Institute of Medical Sciences, New Delhi
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- JIPMER, Puducherry - NEW
- Jolly Grant Medical College, Dehradun - NEW
- Max Super Specialty Hospital, Patparganj, New Delhi - NEW
- Max Super Specialty Hospital, Saket, New Delhi
- Post Graduate Institute of Medical Education & Research, Chandigarh
- Rainbow Hospital, Hyderabad
- Rajiv Gandhi Cancer Institute, New Delhi
- Tata Medical Centre, Kolkata
### InPOG-ACC-16-01

**Multi-site Prospective Study to Determine Household Out-of-Pocket Expenditure Incurred by Families of Children Newly Diagnosed with Cancer in India (HOPE Study)**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Dr Ramandeep Singh Arora</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registered with InPOG</td>
<td>August 2016</td>
</tr>
<tr>
<td>CTRI Registration</td>
<td>CTRI/2016/11/007492</td>
</tr>
<tr>
<td>Recruitment commenced</td>
<td>Yes</td>
</tr>
<tr>
<td>Currently patients recruited</td>
<td>402 (Recruitment Complete)</td>
</tr>
<tr>
<td>Target patient recruitment</td>
<td>380-400</td>
</tr>
<tr>
<td>Anticipated duration of recruitment</td>
<td>1 year</td>
</tr>
<tr>
<td>Centers study open in</td>
<td>15 centres</td>
</tr>
</tbody>
</table>

- All India Institute of Medical Sciences, New Delhi
- Apollo Hospital, Chennai
- Asian Institute of Oncology, Mumbai
- BJ Wadia Hospital, Mumbai
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Institute of Child Health, Chennai
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Safdarjung Hospital, New Delhi
- Saroj Gupta Cancer Centre and research Institute, Kolkata
- SION Hospital, Mumbai
- Sri Ramachandra Medical Centre, Chennai
- Tata Medical Centre, Kolkata
- Tata Memorial Hospital, Mumbai

### InPOG-ACC-16-03

**Exploring Barriers and Enablers to Accessing Care for Childhood Cancers in India: A Multi-centre Qualitative Study**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Dr Ramandeep Singh Arora</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registered with InPOG</td>
<td>May 2017</td>
</tr>
<tr>
<td>Recruitment commenced</td>
<td>Yes</td>
</tr>
<tr>
<td>Currently patients recruited</td>
<td>28 patients + 16 healthcare providers</td>
</tr>
<tr>
<td>Target patient recruitment</td>
<td>30-40 patients + 15-20 healthcare providers</td>
</tr>
<tr>
<td>Anticipated duration of recruitment</td>
<td>3 months</td>
</tr>
<tr>
<td>Centers study open in</td>
<td>6 centres</td>
</tr>
</tbody>
</table>
- Indo-American Cancer Institute, Hyderabad - NEW
- Indraprastha Apollo Hospital, New Delhi
- Institute Rotary Cancer Hospital, AIIMS, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- MNJ Cancer Hospital, Hyderabad - NEW
- Rainbow Hospital, Hyderabad - NEW

**InPOG-HIST-17-01**

**Indian Hemophagocytic Lymphohistiocytosis Registry (I-HLH): Establishment of a nationwide prospective web-based registry for patients diagnosed with HLH**

- Principal Investigator: Dr Mukesh Desai
- Registered with InPOG: July 2017
- CTRI Registration: Ongoing
- Recruitment commenced: Yes
- Currently patients recruited: 1
- Target patient recruitment: 300
- Anticipated duration of recruitment: 5 years
- Centers study open in: 4 centres

- Max Smart Super Specialty Hospital, Saket, New Delhi - NEW
- Max Super Specialty Hospital, Saket, New Delhi - NEW
- Max Super Specialty Hospital, Patparganj, New Delhi - NEW
- Kanchi Kamakoti Childs Trust Hospital, Chennai - NEW

**InPOG-RARE-17-01**

**Clinical Course, Pathological Spectrum and Outcomes in Paediatric Rare Tumours in India: A Multicentric Observational Study**

- Principal Investigator: Dr Maya Prasad
- Registered with InPOG: July 2017
- CTRI Registration: No
- Recruitment commenced: No
- Currently patients recruited: N/A
- Target patient recruitment: 250
- Anticipated duration of recruitment: 1 year
- Centers study open in: NA
InPOG studies granted provisional registration

1. **InPOG-SUPP-16-02 (P)**. A prospective randomized study comparing the safety and cost-effectiveness of antibiotic discontinuation without neutrophil recovery versus with neutrophil recovery in Low-risk febrile-neutropenic children with cancer. **PI:** Brijesh Arora

2. **InPOG-SCT-16-01 (P)**. Post HSCT outcome in pediatric Acute Lymphoblastic Leukemia. A Multicentre observational study. **PI:** Sunil Bhat

3. **InPOG-CML-16-01 (P)**. Study of treatment and outcome of chronic myeloid leukemia in children and adolescents in India. **PI:** Deepak Bansal

4. **InPOG-EPI-16-01 (P)**. Association of gender and childhood cancer registration in India. **PI:** Hari Sankaran

5. **InPOG-WT-16-01 (P)**. Indigenously developed Wilms Tumor Protocol. **PI:** Sameer Bakhshi

6. **InPOG-CANGEN-16-01 (P)**. Evaluation of underlying genetic predisposition for acute myeloid leukemia in children and young adults. **PI:** IC Verma

7. **InPOG-LIV-16-01 (P)**. The Indian Paediatric Liver tumour study (IPLT Study) Indian Paediatric Liver Tumour Registry: Multicentre study. **PI:** T Priyakumari

8. **InPOG-ACC-16-02 (P)**. ACCESSing Childhood Cancer Care in India. **PI:** Ramandeep Arora

9. **InPOG-HL-17-02 (P)** Prospective Collaborative Study for Relapsed/Refractory Hodgkin Lymphoma. **PI:** Amita Mahajan

10. **InPOG-LE-17-02(P)** Cross-Sectional Study of Late Effects in Long term Survivors of Childhood Hodgkin Lymphoma. **PI:** Maya Prasad

11. **InPOG-RARE-17-02 (P)** A Multicenter, prospective, pilot study on use of platinum-based chemotherapy for pediatric nasopharyngeal carcinoma and exploration of the role of peripheral (whole) blood Epstein-Barr virus (EBV)-DNA PCR in predicting outcome and detecting relapse. **PI:** Anirban Das

12. **InPOG-RB-17-01 (P)** A Prospective Collaborative Study for Newly Diagnosed patients with Retinoblastoma. **PI:** Santosh Honavar
## InPOG Structure and Contacts

### 2015-2017

**InPOG Executive**

- Sameer Bakhshi (Chair)
- Amita Trehan (Co-Chair)
- Deepak Bansal
- Tulika Seth
- Venkatraman Radhakrishnan
- Ramandeep Arora

**Subcommittee Chairs**

<table>
<thead>
<tr>
<th>ALL</th>
<th>Vaskar Saha</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML</td>
<td>Sameer Bakhshi</td>
</tr>
<tr>
<td>Ch Myelop</td>
<td>Deepak Bansal</td>
</tr>
<tr>
<td>HL</td>
<td>Jagdish Chandra</td>
</tr>
<tr>
<td>NHL</td>
<td>Amita Trehan</td>
</tr>
<tr>
<td>Histiocytosis</td>
<td>Gaurav Narula</td>
</tr>
<tr>
<td>CNS</td>
<td>Girish Chinnaswamy</td>
</tr>
<tr>
<td>NBL</td>
<td>Satya Yadav</td>
</tr>
<tr>
<td>Retino</td>
<td>Santosh Honavar</td>
</tr>
<tr>
<td>Renal</td>
<td>Sandeep Agarwala</td>
</tr>
<tr>
<td>Liver</td>
<td>Priyakumari</td>
</tr>
<tr>
<td>PNET</td>
<td>Bivas Biswas</td>
</tr>
<tr>
<td>Osteo</td>
<td>Tushar Vora</td>
</tr>
<tr>
<td>STS</td>
<td>Sajid Qureshi</td>
</tr>
<tr>
<td>GCT</td>
<td>Venktraman Radhakrishnan</td>
</tr>
<tr>
<td>Rare, epith</td>
<td>Maya Prasad</td>
</tr>
<tr>
<td>HSCT</td>
<td>SunilBhat</td>
</tr>
<tr>
<td>Acc to Care</td>
<td>Shalini Jatia</td>
</tr>
<tr>
<td>Supportive</td>
<td>Ramandeep Arora</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>Nita Radhakrishnan</td>
</tr>
</tbody>
</table>

### 2018-2020

**InPOG Executive**

- Sripad Banavali (Chair)
- Revathy Raj (Co-Chair)
- Ramandeep Arora (Sec)
- Amita Mahajan
- Girish Chinnaswamy
- Nita Radhakrishnan

**Subcommittee Chairs**

<table>
<thead>
<tr>
<th>ALL</th>
<th>Shekhar Krishnan</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML</td>
<td>Smita Kayal</td>
</tr>
<tr>
<td>Ch Myelop</td>
<td>Tulika Seth</td>
</tr>
<tr>
<td>HL</td>
<td>Amita Mahajan</td>
</tr>
<tr>
<td>NHL</td>
<td>Manas Kalra</td>
</tr>
<tr>
<td>Histiocytosis</td>
<td>Revathy Raj</td>
</tr>
<tr>
<td>CNS</td>
<td>Anirban Das</td>
</tr>
<tr>
<td>NBL</td>
<td>Vikramjit Kanwar</td>
</tr>
<tr>
<td>Retino</td>
<td>Santosh Honavar</td>
</tr>
<tr>
<td>Renal</td>
<td>Shalini Mishra</td>
</tr>
<tr>
<td>Liver</td>
<td>Sandeep Agarwala</td>
</tr>
<tr>
<td>PNET</td>
<td>Atul Batra</td>
</tr>
<tr>
<td>Osteo</td>
<td>Ashish Gulia</td>
</tr>
<tr>
<td>STS</td>
<td>Arpita Bhattacharya</td>
</tr>
<tr>
<td>GCT</td>
<td>Venktraman Radhakrishnan</td>
</tr>
<tr>
<td>Rare, epith</td>
<td>Harsha Prasad</td>
</tr>
<tr>
<td>HSCT</td>
<td>Satya Yadav</td>
</tr>
<tr>
<td>Acc to Care</td>
<td>Shruti Kakkar</td>
</tr>
<tr>
<td>Supportive</td>
<td>Leni Mathew</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>Hari Sankaran</td>
</tr>
<tr>
<td>Late effects</td>
<td>Rachna Seth</td>
</tr>
<tr>
<td>Palliative</td>
<td>Gayatri Palat</td>
</tr>
<tr>
<td>Can Genetics</td>
<td>Nita Radhakrishnan</td>
</tr>
</tbody>
</table>
InPOG Executive 2015-2017*

*DrTulika Seth is also in the Executive

InPOG Executive 2018-2020